Leerink Partnrs Has Negative Estimate for AVDL Q3 Earnings

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) – Investment analysts at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for shares of Avadel Pharmaceuticals in a report issued on Monday, October 6th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($0.11) per share for the quarter, down from their prior estimate of $0.05. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at $0.75 EPS, FY2027 earnings at $1.25 EPS, FY2028 earnings at $1.80 EPS and FY2029 earnings at $2.70 EPS.

A number of other research analysts have also issued reports on AVDL. Wells Fargo & Company upgraded Avadel Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 3rd. UBS Group boosted their price target on Avadel Pharmaceuticals from $13.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 21st. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Avadel Pharmaceuticals in a research report on Friday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avadel Pharmaceuticals in a research report on Wednesday. Finally, Lifesci Capital upgraded Avadel Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Avadel Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $20.86.

Avadel Pharmaceuticals Price Performance

NASDAQ:AVDL opened at $14.20 on Thursday. Avadel Pharmaceuticals has a 12-month low of $6.38 and a 12-month high of $16.66. The firm has a market capitalization of $1.38 billion, a P/E ratio of -473.33 and a beta of 1.46. The business has a 50 day simple moving average of $14.51 and a 200 day simple moving average of $10.93.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The business had revenue of $68.13 million during the quarter, compared to the consensus estimate of $60.28 million. During the same period in the previous year, the business earned ($0.14) EPS. The business’s quarterly revenue was up 64.1% on a year-over-year basis. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Avadel Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Brandes Investment Partners LP raised its position in shares of Avadel Pharmaceuticals by 14.5% during the second quarter. Brandes Investment Partners LP now owns 6,487,642 shares of the company’s stock worth $57,416,000 after purchasing an additional 820,467 shares during the period. Two Seas Capital LP raised its position in shares of Avadel Pharmaceuticals by 24.4% during the second quarter. Two Seas Capital LP now owns 6,155,074 shares of the company’s stock worth $54,472,000 after purchasing an additional 1,208,625 shares during the period. Wealth Effects LLC raised its position in shares of Avadel Pharmaceuticals by 1.1% during the first quarter. Wealth Effects LLC now owns 2,369,122 shares of the company’s stock worth $18,550,000 after purchasing an additional 24,992 shares during the period. Geode Capital Management LLC raised its position in shares of Avadel Pharmaceuticals by 82.3% during the second quarter. Geode Capital Management LLC now owns 2,169,018 shares of the company’s stock worth $19,198,000 after purchasing an additional 979,422 shares during the period. Finally, Kennedy Capital Management LLC raised its position in shares of Avadel Pharmaceuticals by 30.1% during the second quarter. Kennedy Capital Management LLC now owns 981,271 shares of the company’s stock worth $8,684,000 after purchasing an additional 227,228 shares during the period. 69.19% of the stock is owned by institutional investors and hedge funds.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.